NEW YORK, Sept. 23, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Rockwell Medical, Inc. (NASDAQ: RMTI)
Class Period: November 8, 2017 - June 26, 2018
Lead Plaintiff Deadline: September 25, 2018
Join the action: http://www.zlk.com/pslra-d/rockwell-medical-inc?wire=3

About the lawsuit: Throughout the class period, Rockwell Medical, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.

To learn more about the Rockwell Medical, Inc. class action contact jlevi@levikorsinsky.com.

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH)
Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018
Lead Plaintiff Deadline: September 25, 2018
Join the action: http://www.zlk.com/pslra-d/tetraphase-pharmaceuticals-inc?wire=3

The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and (3) consequently, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Tetraphase Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.

Helios and Matheson Analytics Inc. (NASDAQCM: HMNY)
Class Period: August 15, 2017 - July 26, 2018
Lead Plaintiff Deadline: October 1, 2018
Join the action: http://www.zlk.com/pslra-d/helios-and-matheson-analytics-inc?wire=3

About the lawsuit: Helios and Matheson Analytics Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Helios was touting MoviePass’ valuation and path to profitability; (ii) MoviePass’ business model was not sustainable, (iii) consequently, Helios would run out of cash, (iv) Defendants’ actions were only reducing shareholder value, and (v) as a result of the foregoing, Defendants’ statements about Helios’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

To learn more about the Helios and Matheson Analytics Inc. class action contact jlevi@levikorsinsky.com.

GDS Holdings Limited (NASDAQ: GDS)
Class Period: November 2, 2016 - July 31, 2018
Lead Plaintiff Deadline: October 1, 2018
Join the action: http://www.zlk.com/pslra-d/gds-holdings-limited?wire=3

About the lawsuit: During the class period, GDS Holdings Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company has overstated its utilization and occupancy rates; (2) the Company has made acquisitions with related parties at inflated prices; (3) it has used suspect capital and debt raisings despite large off-shore cash reserves; (4) it has adopted unorthodox accounts receivable and payable practices; and (5) that, as a result of the foregoing, Defendant's statements about GDS' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the GDS Holdings Limited class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.